This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
spk03: Good morning, everyone, and welcome to the BioFrontera Inc. second quarter 2023 financial results and business update conference call. At this time, all participants are in a listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's prepared remarks, there will be an opportunity to ask questions. To ask a question, you may press star and then one on your telephone keypad. To draw your questions, you may press star and two. Please also note today's event is being recorded, and at this time I'd like to turn the floor over to Tirth Patel with LHA Investor Relations. Please go ahead.
spk02: Good morning, and welcome to BioFrontera, Inc.' 's second quarter 2023 financial results and business update conference call. Please note that certain information discussed during today's call by management is covered under the safe harbor provisions of the Private Securities Litigation Reform Act. We caution listeners that BioFrontier's management will be making forward-looking statements and that actual results may differ materially from those stated or implied by these forward-looking statements due to risks and uncertainties associated with the company's business. All risks and uncertainties are detailed in and are qualified by the cautionary statements contained in BioFrontier's press releases and SEC filings. Also, this conference call contains time-sensitive information that is accurate only as of the date of the live broadcast, August 11th, 2023. Biofrontera undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this conference call, except as required by law. During today's call, there will be references to certain non-GAAP financial measures. Biofrontera believes these measures provide useful information for investors, yet should not be considered as a substitute for GAAP nor should they be viewed as a substitute for operating results determined in accordance with GAAP. A reconciliation of non-GAAP to GAAP results is included in this morning's press release. More specifically, management will be referring to adjusted EBITDA, a non-GAAP financial measure defined as net income or loss, excluding interest, income and expense, income taxes, depreciation and amortization, and certain other non-recurring or non-cash items. With that, I would now like to turn the call over to Hermann Lubert, CEO, Chairman, and Founder of Biofrontera. Hermann?
spk06: Yeah, thank you, Teroth, and my thanks to everyone joining us this morning. On today's call, I'll provide an overview of our growth strategy and our accomplishments during the second quarter that helps lay the groundwork for many value-driving initiatives. Fred Leffler, our CFO, will follow with a discussion on financial results, and then both of us will be available to answer questions. Starting with the business update, we have made tremendous progress across three critical areas, including expanding our sales force, optimizing our cost structure, and advancing R&D and clinical initiatives. Regarding sales, I would like to commend the team as we announced net revenue of $5.8 million, a 31% increase for the quarter year over year. While Amelus makes up the vast majority of the revenue, we are proud to also share that 55 BF Rodolet lamps were placed at physician offices during the quarter, more than twice the number a year ago. The growing number of lamps in the field reflects both first-term installations and adding lamps among dermatologists already familiar with Amelus PDT. More specifically, of the 55 installations, approximately 20 sites already had one lamp in place and bought a second lamp to provide more Amelus PDT to their patients. The remaining about 35 offices are now set up to start Amelus BF Rodolet PDT. Clearly, LAMP placements are a proxy for future growth, and we are delighted with the increasing recognition of Amelus PDT as an effective and patient-friendly treatment for actinic keratosis. During last quarter's call, we introduced our strategy for growing the sales team. We have achieved our goal of reaching 40 members. Subsequent to growing the sales force, we have also grown the medical and, with a new focus, reimbursement support. On today's call, I'll share some of the strategic shifts in our approach and how we intend to best utilize and support our sales force. To compensate for new strategic hirings, we have reduced the workforce in other parts of the business. Certain metropolitan regions have consistently shown high sales results and great potential. To maintain a leaner and more strategic path of optimizing for growth, we are adopting a more surgical approach to our sales strategy. We will be channeling more resources, both in terms of human capital and medical affairs and reimbursement support initiatives. into metropolitan sales territories that have demonstrated high revenue potential. This includes enhanced training for our existing sales teams in these areas, expanded marketing campaigns, and a potential increase in the number of sales representatives down the road. On the flip side, for regions that have been generating comparatively lower revenues and a lower return on invested assets, we have decided not to expand our sales teams or build out new territories. And in certain cases, we have redeployed those resources to areas with greater opportunity. This shift is being driven by data and optimizes our marketing stand. By being smarter and more intentional with our sales efforts, we are able to recalibrate our strategy if needed and ensure that we stay agile and responsive to market demands. By homing in on high-value metals, we can achieve better growth towards profitability. During Q2, we made the difficult decision to implement a small reduction in force. The reduction was centered primarily around roles less crucial to our current phase of growth. This decision was driven by the necessity to streamline our operations and to reduce costs. However, while we took a step back in certain areas, we simultaneously took two steps forward in others, such as bolstering higher revenue generating positions. By dialing in these adjustments, we have positioned BioFrontera to be leaner and more agile with a heightened focus on driving revenues. Let me turn now to the innovation and R&D taking place at BioFrontera. A key value driver is our portfolio of active label expansion studies for amylose. Just yesterday, we announced that enrollment of all 186 patients is now complete in the phase three clinical study evaluating amylose PDT in combination with BF-Rodolat for the treatment of superficial basal cell carcinoma, or SBCC. Approximately two-thirds of non-melanoma skin cancer cases in the U.S. are BCC, leading to a significant unmet medical need for more effective, less invasive, and cost-efficient therapies that treat BCC as well as underlying pre-malignancies without ionizing radiation. We look forward to sharing results from this phase three study in mid-2024. Adding SBCC to the label of Amelus will allow doctors, in addition to treating individual SBCC lesions, to include these lesions into the treatment of larger sun-damaged fields with Amelus BF-Rodolat PDT as it is currently approved for actinic keratosis. It is the next logical step in our goal to offer one field-directed treatment for all sun-induced neoplastic damage in larger skin areas. Regarding expanding the amyloose label within actinic keratosis, there is a large and growing demand for a highly effective therapy to treat AK beyond the face and scalp. We have an ongoing phase three study evaluating the use of amyloose PDT in the extremities, neck, and trunk currently enrolling. and have dosed 58 patients across 10 centers. We aim to enroll a total of 156 subjects stratified by body region. Lastly, after the final patient completed the clinical phase of the study, we are currently analyzing results from our open-label multi-center phase one safety and tolerability study, investigating three tubes of amulose per treatment. This safety study has the potential to be the final study required for FDA approval for the three-tube treatment. Results will be available very soon as we remain on track for an FDA submission before year end. As most of you are aware, our PDT lamps, BF Rodolat and Rodolat XL, are remarkable solutions in dermatology and the only red lights approved by the FDA for use in photodynamic therapy. However, the current infrastructure for PDT is mostly fixed and limited to dermatology clinics or specialized facilities. Recognizing the constraints posed by the stationary nature of current PDT labs and the growing demand for flexibility and treatment locations, In June, we have announced the inquiry of two granted US patents and the engagement of a contract manufacturer to develop a new, low-cost, portable PDT lamp. The prototype is now under development and aims to deliver the quality of the Rodolet lamps in a new and more accessible form, designed with both the physician and the patient in mind. The lamp is designed to be compact and lightweight, enabling easy storage and allowing clinicians to bring the lamp to the patient. Its portability allows it to be an option at physicians' offices with space constraints, for mobile dermatology clinics, and for reaching remote or underserved areas. A portable lamp will furthermore expand our reach to more dermatologists and more offices. From a sales perspective, it allows our sales team to give live demonstrations at physician offices. Being portable, a lamp can be transported in the back of a car or be presented easily at conferences. Our portable PDT lamp embodies BioFrontera's commitment to innovative solutions that prioritize care and expand access. I look forward to keeping you updated during the development process. As final example of our commitment to patient care and innovation, during the second quarter, we were granted a new patent related to a PDG protocol that is expected to be less painful but equally as effective. With an incubation between application of the gel with exposure to light, with a wavelength spectrum similar to sunlight, followed by 10 minutes of red light illumination, this novel protocol is far more patient-friendly. This is the fourth patent protecting Amalus granted by the U.S. Patent Office in the last 18 months, and it expires in April 2039. Friendlier protocols will help to enable high-efficacy PDT for more patients. and R&D will boost access to PDT. We look forward to providing updates on all these programs and more later this year. With that, I turn the call over to Fred to walk through the financial details of the quarter. Fred?
spk01: Thank you, Hermann. Net revenue was 5.8 million for the three months ended June 30th, 2023, an increase of 1.4 million or 31% over the prior year. For the first six months, net revenue was 14.6 million compared to 14.2 million last year. This growth was driven by higher Amaluz volumes due largely to our Salesforce expansion and higher adoption of Amaluz by dermatologists, even with an absence of any buy-in impact due to a price increase. As a reminder, in 2022, we increased the price for Amaluz by 5% on April 1st. causing dermatologists to accelerate some of their purchases into Q1. We have not raised the price of amylose in 2023, and thus revenues in Q2 2023 were not impacted by any such actions, and we are still ahead of our 2022 revenues, indicating strong growth and a solid second half of the year. Total operating expenses were $14.5 million for the second quarter of 2023 compared with $10.7 million for the second quarter of 2022 and $28.7 million year-to-date compared with $23.5 million for the first six months of last year. The cost increase of $5.2 million was driven by approximately $3 million due to our Salesforce expansion and increased investment in medical affairs and reimbursement, along with some severance costs as we pivoted resources to more revenue generating roles, as Herman mentioned. And approximately $1.7 million of the increase was due to one-time legal fees from a settlement of litigation in the first half of 2023. Cost of revenue for the quarter was $2.9 million, which was about 13% higher than the second quarter last year and reflects higher sales of amylose. Cost of revenue for the first six months was $7.5 million compared with $7.7 million last year. Selling general and administrative expenses were $11.5 million for the quarter up approximately 15%. For the first six months of this year, SG&A expenses were $21.4 million compared with $17.7 million in the first six months of 2022. As I mentioned, the increase was primarily driven by realigning SG&A costs into revenue generating functions, the expansion of our sales force, and also includes the non-recurring legal expenses. The net loss for the second quarter of 2023 was $9.8 million, or $7.23 per share, and this compares with a net loss of $850,000, or $0.90 per share, for the prior year quarter. I will note that these figures are on a post-split basis. Net loss for the first six months of 2023 was $17.3 million, compared with a net income of $4.7 million for the first six months of 2022, which was primarily a result of the change in the fair value of outstanding warrants. As net income or loss comprises multiple non-cash items, we refer to adjusted EBITDA for a better representation of the business's status. Adjusted EBITDA was negative $7.9 million for the quarter compared with negative $7.1 million last year. The decrease was driven by higher SG&A costs, partially offset by increased revenues. Adjusted EBITDA for the first six months of the year was negative $11.8 million compared to $9.5 million during the same period in 2022. I refer you to the table in the news release we issued earlier this morning for reconciliation of GAAP to non-GAAP financial measures. Turning to our balance sheet, as of June 30th, we had cash and cash equivalents of $4.5 million compared with $17.2 million as of December 31st of 2022. Aside from operations, we have spent more on inventory in 2023 than I would like. Due to some lingering supply chain concerns into early 2022, we increased inventory orders in 2023. We are not anticipating making any inventory purchases for the first half of 2024 as a result, and we will continue to manage our working capital very closely. Based on the quarter's strong results, we are on track to hit our previously announced goals. With an optimized sales force able to produce higher returns along with label expansion opportunities advancing on track, we are affirming our 2023 financial guidance. With the strongest months for PDP ahead of us and based on multiple positive indicators for the year so far, we expect at least 25% growth in revenue compared with 2022 and expect
spk03: to be cash flow positive within approximately one and a half years so with that overview of our business and recent financial performance herman and i are now ready to take questions from our covering analysts operator ladies and gentlemen at this time we'll begin the question and answer session to ask a question you may press star and one to withdraw your questions you may press star and two our first question today comes from jonathan asha from Please go ahead with your question.
spk05: Thank you, guys, and good morning. Sorry if you've mentioned this in the call. I'm juggling three calls myself. Did you update acne and trunk extremity enrollment? Or if you did not, can you repeat it?
spk06: We updated enrollment of the trunk and extremities. That study has enrolled by now 58 patients. We did not update the ACNA enrollment, and I would have to look at that for a few minutes. Maybe if you go on with the questions, I'll...
spk05: Yes, Herman, I can buy you that time by asking a financial question. The SG&A, how is that going to look to the best that you're comfortable giving? You know, that was a decent top second quarter. So how much of that is one-time stuff?
spk01: So one-time, I guess. don't have that number off of the top of my head, i.e. the severance, but the run rate savings that's excluding the increase in sales force is expected to be about $1.8 million after the severance is cleared out and we hire one more position that we were in the reimbursement area.
spk05: Okay, so it could be a little more than, say, $10 million a quarter, something like that maybe.
spk01: Maybe a little less than $10 million a quarter.
spk05: Okay, all right, even better. So do you think the third quarter sequentially goes up, given that there was no 1Q price hike? Do you think that is something that will facilitate a bit more smooth revenue than you've had in prior years?
spk01: Yes, we are expecting the third and fourth quarter to be higher.
spk05: Hopefully the fourth quarter is substantially higher. Yes. That should be a very strong bit of growth. Herman, if you still want some more time, I can ask. I can give you the number. Okay. For acne, what is it?
spk06: It's 56 out of 126.
spk05: Thank you very much. And the 58 patients of trunk extremities, out of how many wanted? 165, great. So my last question is, did you guys lose any of the people you hired when you hired that bolus of sales and marketing people?
spk06: We always have, like every company, we have a certain turnover of people, but not higher than other companies. We are pretty much on the average of companies of all kinds. We did not specifically lose people when we realigned the sales regions.
spk05: Okay. That's all I have. Thank you very much.
spk03: Our next question comes from Bruce Jackson from the Benchmark Company. Please go ahead with your question.
spk04: Good morning, and thank you for taking my questions. I wanted to get back to the seasonality in sales, just so I understand this correctly. Now, with the price increase you were talking about, is it this year or next year you're not taking the price increase?
spk01: Hi, Bruce. So we have not taken a price increase since April 1st of 2022, and we are evaluating, you know, when we should do that and what that should be.
spk04: Okay. And then, and so when we're looking at the back half of this year, will it follow that standard pattern where the fourth quarter is the biggest quarter of the year? Because in the past, sometimes you had the forward buying in anticipation of the price increase in the following year. So I'm just trying to kind of get my arms around this.
spk01: Understood. So if there is some sort of price increase, we would expect to see significant buy-in, as we mentioned, that happened in the March, late February, early March of 2022. But typically business goes up in the third and fourth quarter naturally as well. So like I said, we're evaluating different scenarios as far as the price increase goes. But regardless, we expect the third quarter and fourth quarter to have significant growth.
spk04: Okay, good. That's helpful. Then I wanted to just congratulate you on getting the BCC trialed and enrolled. That's been a major ordeal for you. Nice to have that complete. Can you help me understand how the pieces are going to come together with this approval? You said that the next step is field treatment with the BCC lesions included. Do you have to get a separate label for that? Or with the data that you have now from this trial, can you immediately go to doing the field therapy with the different lesion types?
spk06: We have field therapy with amalus in the label already for actinic keratosis. And what it basically means is that we can, if we have a piece of skin, an area of skin with several actinic keratosis lesions, then we can treat that entire area, but not only the diseased spots. So we can basically treat healthy skin assuming that maybe under that healthy skin there are other things hiding that are not yet visible. So that's what we have in the label. And getting BCC approval, what that means is that if one of these areas, which is heavily sun damaged, has multiple AKs and other sun damage, cosmetic sun damage maybe, if that also has superficial BCCs, then they can be treated along with the field treatments that we provide to the patient. So we do not need field treatment specifically for BCC.
spk04: OK. And then when we get the three tube data submitted, then theoretically then sometime, if that's end of the year then, It's pretty much all systems are go for the field treatment then in 2024 and getting that out to the physicians.
spk06: Yes. So the free tube is important, has been holding us back since a number of years, the fact that we can only do one tube. So with this as the final study, if we got that into the label towards the middle of next year, this should be a big jump in sales actually.
spk04: Okay, great. All right, that's it for me. Thank you.
spk03: And ladies and gentlemen, with that, we'll be concluding today's question and answer session. I'd like to turn the floor back over to Herman for any closing remarks.
spk06: Thank you all for those questions. And thank you to all the listeners. To summarize, I'm very encouraged by the strong sales growth we have delivered this past quarter and the increase in the number of BF Rotterdam installations. As mentioned, we remain on track to grow revenues by 25% this year, driven primarily by Amelus sales and the maturing sales force. We look forward to speaking with you again when we report our third quarter 2023 results. Thank you and have a nice day.
spk03: Ladies and gentlemen, with that, we'll conclude today's conference call and presentation. We thank you for joining. You may now disconnect your lines.
Disclaimer